At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Aripiprazole + Cocaine +1 moredrug
Likely dose
Aripiprazole + Cocaine 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Aripiprazole on Cocaine Craving and Self-Administration
In Brief
A Phase 2 clinical trial evaluating Aripiprazole + Cocaine and Placebo + Cocaine for Cocaine Abuse. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate whether aripiprazole will decrease cocaine self-administration, subjective effects and cravings compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Abuse
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2005
First PostedSep 2006
Primary CompletionAug 2008
Study CompletionSep 2008
TodayJul 2026
First PostedSep 8, 2006
Enrollment StartApr 1, 2005
Primary CompletionAug 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.8 years ago
Interventions
Aripiprazole + Cocainedrug
Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
Placebo + Cocainedrug
Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).